$6.99
0.87% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US09075A1088
Symbol
BVS

Bioventus Inc - Ordinary Shares - Class A Stock price

$6.99
-0.51 6.80% 1M
-4.42 38.74% 6M
-3.51 33.43% YTD
+0.76 12.20% 1Y
-1.47 17.38% 3Y
-6.01 46.23% 5Y
-6.01 46.23% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.06 0.87%
ISIN
US09075A1088
Symbol
BVS
Sector

Key metrics

Market capitalization $463.84m
Enterprise Value $834.26m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 34.86
EV/Sales (TTM) EV/Sales 1.47
P/S ratio (TTM) P/S ratio 0.82
P/B ratio (TTM) P/B ratio 3.13
Revenue growth (TTM) Revenue growth 8.60%
Revenue (TTM) Revenue $567.70m
EBIT (operating result TTM) EBIT $31.90m
Free Cash Flow (TTM) Free Cash Flow $23.93m
Cash position $22.80m
EPS (TTM) EPS $-0.49
P/E forward 17.33
P/S forward 0.82
EV/Sales forward 1.48
Short interest 3.84%
Show more

Is Bioventus Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Bioventus Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Bioventus Inc - Ordinary Shares - Class A forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a Bioventus Inc - Ordinary Shares - Class A forecast:

Buy
67%
Hold
33%

Financial data from Bioventus Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
568 568
9% 9%
100%
- Direct Costs 192 192
2% 2%
34%
375 375
12% 12%
66%
- Selling and Administrative Expenses 280 280
19% 19%
49%
- Research and Development Expense 14 14
15% 15%
2%
82 82
6% 6%
14%
- Depreciation and Amortization 50 50
6% 6%
9%
EBIT (Operating Income) EBIT 32 32
6% 6%
6%
Net Profit -32 -32
46% 46%
-6%

In millions USD.

Don't miss a Thing! We will send you all news about Bioventus Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bioventus Inc - Ordinary Shares - Class A Stock News

Neutral
Seeking Alpha
14 days ago
Bioventus Inc. (NASDAQ:BVS ) Q1 2025 Results Conference Call May 6, 2025 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President & Chief Executive Officer Mark Singleton - Senior Vice President & Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig Hallum Robbie Marcus - JPMorgan Operator Good day, and welcome to the Bioventus Fir...
Neutral
GlobeNewsWire
15 days ago
DURHAM, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 29, 2025.
Neutral
GlobeNewsWire
23 days ago
DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market opens on Tuesday, May 6, 2025.
More Bioventus Inc - Ordinary Shares - Class A News

Company Profile

Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from a array of musculoskeletal conditions. It operates through four segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on December 22, 2015 and is headquartered in Durham, NC.

Head office United States
CEO Robert Claypoole
Employees 930
Founded 2011
Website www.bioventus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today